| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELA3A |
| Uniprot No | P09093 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-270aa |
| 氨基酸序列 | VVHGEDAVPYSWPWQVSLQYEKSGSFYHTCGGSLIAPDWVVTAGHCISRDLTYQVVLGEYNLAVKEGPEQVIPINSEELFVHPLWNRSCVACGNDIALIKLSRSAQLGDAVQLASLPPAGDILPNKTPCYITGWGRLYTNGPLPDKLQQARLPVVDYKHCSRWNWWGSTVKKTMVCAGGYIRSGCNGDSGGPLNCPTEDGGWQVHGVTSFVSAFGCNFIWKPTVFTRVSAFIDWIEETIASH |
| 预测分子量 | 42.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ELA3A重组蛋白的参考文献示例(注：部分内容可能为模拟或概括性描述，仅供参考)：
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant Human ELA3A in Escherichia coli"
**作者**: Zhang, L., et al.
**摘要**: 本研究报道了在大肠杆菌系统中高效表达人源ELA3A重组蛋白的优化策略。通过密码子优化和诱导条件调控，成功获得可溶性蛋白，并利用镍柱亲和层析纯化。酶活性分析显示重组ELA3A具有弹性蛋白酶特异性底物水解能力，为后续结构研究奠定基础。
2. **文献名称**: "Proteolytic Activity of Recombinant ELA3A in Pancreatic Disease Models"
**作者**: Smith, J.R., & Tanaka, K.
**摘要**: 研究团队在HEK293细胞中表达重组ELA3A，并验证其在胰腺炎相关病理模型中的功能。结果显示，ELA3A重组蛋白可降解细胞外基质成分，其活性受内源性抑制剂调控，提示其在胰腺组织重塑中的潜在作用。
3. **文献名称**: "Structural Insights into ELA3A: Crystallization and Mutational Analysis of the Recombinant Enzyme"
**作者**: Gupta, S., et al.
**摘要**: 通过杆状病毒-昆虫细胞系统表达ELA3A重组蛋白，获得高纯度样品用于结晶。X射线衍射解析了其三维结构，关键活性位点残基(如His57、Asp102)的突变实验证实了其催化机制与经典丝氨酸蛋白酶的一致性。
4. **文献名称**: "Development of a Novel ELISA Assay Using Recombinant ELA3A for Early Diagnosis of Genetic Disorders"
**作者**: Wang, Y., et al.
**摘要**: 研究利用哺乳动物细胞表达的重组ELA3A蛋白作为抗原，开发了高灵敏度的ELISA检测方法，用于筛查与ELA3A基因突变相关的先天性代谢异常。临床样本验证显示该方法特异性优于传统生化检测。
---
**备注**：以上文献信息为示例性质，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的文章。若需具体文献，建议结合最新研究进行补充。
ELA3A (Elastase 3A) is a member of the elastase family of serine proteases, which play critical roles in degrading extracellular matrix proteins, particularly elastin—a key structural component of connective tissues. Encoded by the *ELA3A* gene in humans, this enzyme is primarily synthesized in the pancreas as an inactive zymogen (pro-elastase) and later activated in the small intestine to participate in dietary protein digestion. Its substrate specificity for elastin and other hydrophobic residues makes it essential for nutrient processing and tissue remodeling.
Recombinant ELA3A protein is engineered using biotechnological platforms, such as *E. coli* or mammalian expression systems, to produce the active enzyme for research and therapeutic applications. The recombinant form retains the catalytic triad (His57. Asp102. Ser195) characteristic of serine proteases, ensuring enzymatic activity. Purification often involves affinity chromatography tags (e.g., His-tag) and refolding steps to achieve proper conformation.
In biomedical research, recombinant ELA3A serves as a tool to study protease-mediated pathways in diseases like chronic pancreatitis, cystic fibrosis, and cancer metastasis, where dysregulated elastase activity contributes to tissue damage or tumor progression. It also aids in drug discovery, enabling the screening of protease inhibitors or modulators. Additionally, ELA3A’s role in pathogen defense and inflammation has spurred interest in its immunoregulatory functions. However, challenges remain in optimizing its stability and minimizing off-target effects in therapeutic contexts. Ongoing studies aim to refine production techniques and explore engineered variants for targeted applications.
×
